OVARIAN CANCER and US: ovarian cancer research

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label ovarian cancer research. Show all posts
Showing posts with label ovarian cancer research. Show all posts

Saturday, April 07, 2012

Fulltext | Epithelial ovarian cancer: A feasible plan for adjunctive treatment using simultaneous acyclovir, ambrisentan, captopril, disulfiram, fluvoxamine-augmented ramelteon, icatibant, imiquimod peritoneal lavage, and plerixafor | Journal of Cancer Therapeutics & Research



Fulltext | Epithelial ovarian cancer: A feasible plan for adjunctive treatment using simultaneous acyclovir, ambrisentan, captopril, disulfiram, fluvoxamine-augmented ramelteon, icatibant, imiquimod peritoneal lavage, and plerixafor | Journal of Cancer Therapeutics & Research

Conclusion


To improve the prognosis in EOC an effort to comprehensively block growth factors that have been identified as active in human EOC as suggested in this paper may prove fruitful. Past research indicates that several already-approved and marketed drugs might do this. The nine drugs have no clearly discernable interaction with each other and none would be expected to interfere with concomitant current cytotoxic chemotherapy regimens although such cannot be excluded. Given the safety of the nine drugs individually, and the poor prognosis of an EOC seeded peritoneum, the risk of unexpected side effects or interaction I believe is worth taking.

Thursday, March 01, 2012

Grants.gov - Opportunity Synopsis - OCRP Ovarian Cancer Academy



The synopsis for this grant opportunity is detailed below, following this paragraph. This synopsis contains all of the updates to this document that have been posted as of 02/27/2012 . If updates have been made to the opportunity synopsis, update information is provided below the synopsis.
If you would like to receive notifications of changes to the grant opportunity click send me change notification emails . The only thing you need to provide for this service is your email address. No other information is requested.

Any inconsistency between the original printed document and the disk or electronic document shall be resolved by giving precedence to the printed document.
Document Type: Grants Notice
Funding Opportunity Number: W81XWH-12-OCRP-OCA
Opportunity Category: Discretionary
Posted Date: Feb 27, 2012
Creation Date: Feb 27, 2012
Original Closing Date for Applications: Jul 18, 2012
Current Closing Date for Applications: Jul 18, 2012
Archive Date: Aug 17, 2012
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 2
Estimated Total Program Funding: $2,400,000
Award Ceiling:
Award Floor:
CFDA Number(s): 12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement: No

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility:

Agency Name

Dept. of the Army -- USAMRAA

Description

The OCRP Ovarian Cancer Academy, which was initially created in FY09, is intended to be a unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty. The overarching goal of the Ovarian Cancer Academy is to develop successful, highly productive ovarian cancer researchers in a collaborative research training environment. The current Ovarian Cancer Academy is a virtual career development and research training platform consisting of seven Early-Career Investigator/Designated Mentor pairs from different institutions and one Academy Dean. The Academy Dean serves as a resource for the Early-Career Investigators and Mentors, assesses the progress of the Early-Career Investigators, and facilitates communication and collaboration among all of the Early-Career Investigators and Mentors.

Link to Full Announcement